FDA Panel Delays Approval Of Clovis' Lung Cancer Drug
A U.S. Food and Drug Administration committee on Tuesday voted 12-1 to delay approval of Clovis Oncology Inc.'s lung cancer drug rociletinib, days after the agency expressed concerns over its effectiveness...To view the full article, register now.
Already a subscriber? Click here to view full article